Article Data

  • Views 619
  • Dowloads 149

Original Research

Open Access

Low-risk gestational trophoblastic neoplastic outcome after primary treatment with low-dose methotrexate from 2005 to 2017

  • Z. Shen1,†
  • Y. Zhou1,*,†,
  • C. Zhu1
  • L. Qian1
  • W. Song1
  • J. Wang1
  • H. Liu1
  • D. Feng2
  • B. Ling2
  • X. Zhang1
  • D. Wu1

1Department of Obstetrics and Gynecology, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, China

2Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

DOI: 10.12892/ejgo4604.2019 Vol.40,Issue 5,October 2019 pp.770-774

Accepted: 31 January 2018

Published: 10 October 2019

*Corresponding Author(s): Y. Zhou E-mail: caddie1234@gmail.com

† These authors contributed equally.

Abstract

Purpose: To retrospectively assess the efficacy and toxicity of single-agent methotrexate (MTX) regimen applied to patients treated in Anhui provincial hospital with low-risk gestational trophoblastic neoplasia (LR-GTN). Materials and Methods: Between 2005 and 2017, on the basis of International Federation of Gynecology and Obstetrics (FIGO 2000) criteria for staging and scoring system, 66 patients with LR-GTN were treated with single-agent MTX. The authors describe their clinical characteristics, resistance/remission/recurrence rates, and treatment toxicity. Results: All patients achieved remission and maintained disease-free status until the moment of analysis. The five-day MTX protocol can achieve a 63.6% remission rate. Resistance to this regimen was obviously related with age and higher pre-treatment hCG. Severe blood toxicity (grade 3 or 4) was shown in four (6.1%) of 66 cases, of which one (1.5%) case was grade 4. Conclusions: For patients diagnosed with LR-GTN, a five-day MTX regimen is an appropriate treatment associating a low rate of toxicity to a high rate of remission.

Keywords

2000 International Federation of Gynecology and Obstetrics scoring; Low-risk gestational trophoblastic neoplasia; Methotrexate; Efficacy; Toxicity

Cite and Share

Z. Shen,Y. Zhou,C. Zhu,L. Qian,W. Song,J. Wang,H. Liu,D. Feng,B. Ling,X. Zhang,D. Wu. Low-risk gestational trophoblastic neoplastic outcome after primary treatment with low-dose methotrexate from 2005 to 2017. European Journal of Gynaecological Oncology. 2019. 40(5);770-774.

References

[1] Essel K.G., Bruegl A., Gershenson D.M., Ramondetta L.M., Naumann R.W., Brown J.: “Salvage chemotherapy for gestational trophoblastic neoplasia: utility or futility?” Gynecol. Oncol., 2017, 74, 146.

[2] Kong Y., Yang J., Jiang F., Zhao J., Ren T., Li J.: “Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: Aretrospective cohort study”. Gynecol. Oncol., 2017, 81, 146.

[3] Seckl M.J., Sebire N.J., Fisher R.A., Golfier F., Massuger L., Sessa C.: “Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 39, 24.

[4] Stevens F.T., Katzorke N., Tempfer C., Kreimer U., Bizjak G.I., Fleisch M.C., Fehm T.N.: “Gestational Trophoblastic Disorders: An Update in 2015”. Geburtshilfe Frauenheilkd, 2015, 1043, 75.

[5] Froeling F.E., Seckl M.J.: “Gestational trophoblastic tumours: an update for 2014”. Curr. Oncol. Rep., 2014, 408, 16.

[6] Miller C.R., CaitlinSledge N.P., LeathIII C.A., Phippen N.T., Havrilesky L.J., Barnett J.C.: “Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?”. Gynecol. Oncol., 2017, 125, 144.

[7] Kohorn E.I.: “The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment”. Int. J. Gynecol. Cancer, 2001, 73, 11.

[8] Yarandi F., Eftekhar Z., Shojaei H., Kanani S., Sharifi A., Hanjani P.: “Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia”. Int. J. Gynaecol. Obstet., 2008, 33, 103.

[9] Liu E., Nealon E., Klausner R.: “Perspective from the National Cancer Institute (NCI)”. Breast Dis., 1998, 29, 10.

[10] Ngan H.Y.: “The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia”. Int. J. Gynecol. Cancer, 2004, 202, 14.

[11] Ngan H.Y., Bender H., Benedet J.L., Jones H., Montruccoli G.C., Pecorelli S.: “Gestational trophoblastic neoplasia, FIGO 2000 staging and classification”. Int. J. Gynaecol. Obstet., 2003, 175, 83.

[12] Lee Y.J., Park J.Y., Kim D.Y., Suh D.S., Kim J.H., Kim Y.M., et al.: “Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease”. J. Gynecol. Oncol., 2017, 8, 28.

[13] Turkmen O., Basaran D., Karalok A., Kimyon G.C., Tasci T., Ureyen I., et al.: “Factors related to treatment outcomes in low-risk gestational neoplasia”. Tumori, 2017, 177, 103.

[14] Verhoef L., Baartz D., Morrison S., Sanday K., Garrett A.J.: “Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC)”. Aust. N. z. J. Obstet. Gynaecol., 2017, 458, 57.

[15] Hammond C.B, Weed J.J., Currie J.L.: “The role of operation in the current therapy of gestational trophoblastic disease.” Am. J. Obstet. Gynecol., 1980, 844, 136.

[16] Lurain J.R., Brewer J.I., Torok E.E., Halpern B.: “Gestational trophoblastic disease: treatment results at the Brewer Trophoblastic Disease Center”. Obstet. Gynecol., 1982, 354, 60.

[17] Mousavi A., Cheraghi F., Yarandi F., Gilani M.M., Shojaei H.: “Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease”. Int. J. Gynaecol. Obstet., 2012, 39, 116.

[18] Soper J.T., Clarke-Pearson D.L., Berchuck A., Rodriguez G., Hammond C.B.: “5-day methotrexate for women with metastatic gestational trophoblastic disease”. Gynecol. Oncol., 1994, 76, 54.

[19] Lurain J.R., Chapman-Davis E., Hoekstra A.V., Schink J.C.: “Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia”. J. Reprod. Med., 2012, 283, 57.

[20] Lurain J.R., Elfstrand E.P.: “Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors”. Am. J. Obstet. Gynecol., 1995, 574, 172.

[21] Chapman-Davis E., Hoekstra A.V., Rademaker A.W., Schink J.C., Lurain J.R.: “Treatment of nonmetastatic and metastatic lowrisk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy”. Gynecol. Oncol., 2012, 572, 125.

[22] McNeish I.A., Strickland S., Holden L., Rustin G.J., Foskett M., Seckl M.J., Newlands E.S.: “Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000”. J. Clin. Oncol., 2002, 1838, 20.

[23] You B., Harvey R., Henin E., Mitchell H., Golfier F., Savage P.M., et al.: “Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements”. Br. J. Cancer, 2013, 1810, 108.

[24] El-Helw L.M., Coleman R.E., Everard J.E., Tidy J.A., Horsman J.M., Elkhenini H.F., Hancock B.W.: “Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia”. Gynecol. Oncol., 2009, 306, 113.

[25] Chalouhi G.E., Golfier F., Soignon P., Massardier J., Guastalla J.P., Trillet-Lenoir V., Schott A.M., Raudrant D.: “Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity”. Am. J. Obstet. Gynecol., 2009, 643, 200.

[26] McGrath S., Short D., Harvey R., Schmid P., Savage P.M., Seckl M.J.: “The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1)”. Br. J. Cancer, 2010, 810, 102.

[27] Taylor F., Grew T., Everard J., Ellis L., Winter M.C., Tidy J., et al.: “The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid”. Eur. J. Cancer, 2013, 3184, 49.

[28] Sita-Lumsden A., Short D., Lindsay I., Sebire N.J., Adjogatse D., Seckl M.J., Savage P.M.: “Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009”. Br. J. Cancer, 2012, 1810, 107.

[29] Gilani M.M., Yarandi F., Eftekhar Z., Hanjani P.: “Comparison of pulse methotrexate and pulse dactinomycin in the treatment of lowrisk gestational trophoblastic neoplasia”. Aust. N. z. J. Obstet. Gynaecol., 2005, 161, 45.

[30] Osborne R.J., Filiaci V., Schink J.C., Mannel R.S., Secord A.A., Kelley J.L., et al.: “Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study”. J. Clin. Oncol., 2011, 825, 29.

[31] Seckl M.J., Sebire N.J., Berkowitz R.S.: “Gestational trophoblastic disease”. Lancet, 2010, 717, 376.

[32] Golfier F., Frappart L., Schott A.M., Raudrant D.: “Aplea for the creation of trophoblastic disease reference centers in France”. J. Gynecol. Obstet. Biol. Reprod. (Paris), 2000, 538, 29.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top